Drug intelligence / Profile preview

Aom0207

Development stage: Preclinical
Lead developer: Hangzhou Adamerck Pharmlabs
Modality: Small Molecules

Overview

Aom0207 is a small molecule drug candidate being developed by Hangzhou Adamerck Pharmlabs for the prevention of intestinal injury and chemotherapy-induced diarrhea (CID). Positioned as a potential first-in-class preventive treatment for CID, the agent aims to mitigate the gastrointestinal toxicity often associated with anti-tumor therapies. As of the latest reports, Aom0207 has completed animal studies and is currently in the preclinical stage of development.

Beyond the preview

Go deeper on Aom0207.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aom0207.

Explore the full profile